HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer

被引：0
|
作者：
Hamilton, Erika P.
Martin, Miguel
O'Sullivan, Ciara Catherine
Curigliano, Giuseppe
Sohn, Joohyuk
Tsurutani, Junji
Tryfonidis, Konstantinos
Santarpia, Libero
Yang, Shan
Dieras, Veronique
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashiville, TN USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Mayo Clin, Rochester, MN USA
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Yonsei Canc Ctr, Seoul, South Korea
[6] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Seagen Inc, Bothell, WA USA
[9] Ctr Eugene Marquis, Rennes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1115
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Iyengar, N. M.
    Smyth, L.
    Lake, D.
    Gucalp, A.
    Singh, J. C.
    Traina, T. A.
    DeFusco, P.
    Dickler, M. N.
    Fornier, M. N.
    Goldfarb, S.
    Jhaveri, K.
    Modi, S.
    Troso-Sandoval, T.
    Argolo, D.
    Jack, K.
    Ulaner, G.
    Jochelson, M.
    Baselga, J.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    CANCER RESEARCH, 2017, 77
  • [42] Phase II study of gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer after prior trastuzumab/pertuzumab- or pertuzumab-based therapy
    Iyengar, N. M.
    Argolo, D.
    Smyth, L.
    Chen, M. F.
    Hudis, C. A.
    Dang, C. T.
    CANCER RESEARCH, 2016, 76
  • [43] Use of pertuzumab in combination with taxanes for HER2+metastatic breast cancer: Analysis of US electronic health records
    Polito, Letizia
    Shim, Jinjoo
    Du Toit, Yolande
    Thy Do
    Knott, Adam
    Sanglier, Thibaut
    CANCER RESEARCH, 2020, 80 (04)
  • [44] Trastuzumab and vinorelbine or taxane chemotherapy for HER2+metastatic breast cancer: The TRAVIOTA study.
    Burstein, H. J.
    Keshaviah, A.
    Baron, A.
    Hart, R.
    Lambert-Falls, R.
    Marcom, P. K.
    Gelman, R.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 40S - 40S
  • [45] CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2010, 10 (06) : 489 - 491
  • [46] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
  • [47] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Datko, F.
    D'Andrea, G.
    Dickler, M.
    Theodoulou, M.
    Goldfarb, S.
    Lake, D.
    Fornier, M.
    Modi, S.
    Sklarin, N.
    Comen, E.
    Fasano, J.
    Gajria, D.
    Drullinsky, P.
    Gilewski, T.
    Murphy, C.
    Syldor, A.
    Lau, A.
    Hamilton, N.
    Patil, S.
    Liu, J.
    Chandarlapaty, S.
    Hudis, C.
    Dang, C.
    CANCER RESEARCH, 2012, 72
  • [48] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases
    Carey, L. A.
    Krop, I.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S510 - S511
  • [49] HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+breast cancer
    Hurvitz, S. A.
    Harbeck, N.
    Vahdat, L.
    Wolff, A. C.
    Tolaney, S. M.
    Loi, S.
    Masuda, N.
    O'Shaughnessy, J.
    Xie, D.
    Walker, L. N.
    Rustia, E.
    Borges, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S75 - S75
  • [50] MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer
    Bekaii-Saab, Tanios S.
    Van Cutsem, Eric
    Tabernero, Josep
    Siena, Salvatore
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    Pratap Singh Raghav, Kanwal
    Cercek, Andrea
    Heinemann, Volker
    Adelberg, David E.
    Ramos, Jorge
    Yang, Shan
    Andre, Thierry
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345